Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CellaVision AB

Market Cap 3.13B 328M 285M 263M 246M 460M 31.45B 470M 1.21B 15.16B 1.23B 1.21B 52.71B P/E Ratio 2026 *
21.6x
P/E Ratio 2027 * 18x
Enterprise Value 2.92B 306M 265M 244M 229M 428M 29.26B 437M 1.13B 14.1B 1.15B 1.12B 49.04B EV / Sales 2026 *
3.78x
EV / Sales 2027 * 3.33x
Free-Float
83.08%
Yield 2026 *
2.09%
Yield 2027 * 2.34%
1 day-16.39%
3 months-14.89%
6 months-19.83%
Current year-19.83%
Current year 13.49
Extreme 13.49
17.3
1 year 13.49
Extreme 13.49
17.3
3 years 13.49
Extreme 13.49
25.9
5 years 13.49
Extreme 13.49
34.75
10 years 13.49
Extreme 13.49
41.48
Manager TitleAgeSince
Chief Executive Officer - 05/06/2026
Director of Finance/CFO 46 02/09/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 61 -
Director/Board Member 62 04/05/2018
Chairman 64 29/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-16.39%-.--% - - 328M
-2.50%-7.77%+10.88%-29.84% 16.47B
+6.03%-2.53%+28.65%+60.84% 1.67B
-0.32%-1.47%-31.12%+19.55% 1.11B
+4.37%-7.91%-54.50%-83.37% 961M
-1.20%-4.29%-24.95%-55.23% 635M
-0.07%-2.76%-47.53%-59.63% 561M
+4.75%+5.45%+26.49%-51.45% 465M
+0.47%-2.60%-54.83%-60.17% 391M
+4.62%-8.55%+47.79% - 337M
Average +0.65%-2.14%-11.01%-32.41% 2.51B
Weighted average by Cap. +1.81%-5.93%+4.62%-25.36%

Financials

2026 *2027 *
Net sales 772M 80.86M 70.17M 64.68M 60.61M 113M 7.74B 116M 299M 3.73B 304M 297M 12.98B 862M 90.38M 78.43M 72.3M 67.74M 127M 8.65B 129M 334M 4.17B 339M 332M 14.5B
Net income 145M 15.19M 13.18M 12.15M 11.38M 21.27M 1.45B 21.71M 56.11M 701M 57.02M 55.79M 2.44B 174M 18.25M 15.84M 14.6M 13.68M 25.56M 1.75B 26.09M 67.42M 842M 68.5M 67.03M 2.93B
Net Debt -218M -22.87M -19.85M -18.29M -17.14M -32.03M -2.19B -32.69M -84.49M -1.06B -85.85M -84M -3.67B -266M -27.87M -24.18M -22.29M -20.89M -39.03M -2.67B -39.84M -103M -1.29B -105M -102M -4.47B
Logo CellaVision AB
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Employees
241
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
131.40SEK
Average target price
179.00SEK
Spread / Average Target
+36.23%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!